Psoriazis ve Eşlik Eden Hastalıklar

Year 2016, Volume: 17 Issue: 3, 121 - 127, 20.07.2016

Derya Uçmak, Zeynep Meltem Akkurt, Mustafa Arica .

Abstract

Psoriazis kronik inflamatuar bir hastalıktır. Psoriazis ile ilgili yapılan çalışmalarda bu inflamatuar durumun klinik yansımasının artık deriye sınırlı olmadığı, eşlik eden bazı inflamatuar hastalıkların psoriaziste normalde beklenenden farklı sayıda olduğu fark edilmiştir. Psoriazisle ilişkili eskiden beri bilinen depresyon ve yaşam kalitesi, psoriatik artrit, malignensi gibi bazı komorbiditelere ek olarak kardiovasküler hastalık, metabolik sendrom, inflamatuar barsak hastalıkları, uyku apne sendromu gibi yeni araştırılan komorbiditeler tanımlanmıştır. Bu derlemede sık görülen komorbiditelerin ve konu ile alakalı yapılmış çalışmalardan bahsedilecektir.

Keywords

İnflamasyon, kardiyovasküler hastalık, komorbidite, metabolik sendrom, psoriazis

References

• Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients beliefs and attitudes towards the disease. Br J Dermatol 1996;135(4):533–7.
• Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113(12):1664-75.
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol ;46(1):1-23. Christophers E. Comorbidities in psoriasis. Clin Dermatol ;25(6):529–34. Flanders WD, Boyle CA, Boring JR. Bias associated with differential hospitalization rates in incident case-control studies. J Clin Epidemiol 1989;42(5):395–401.
• Gottlıeb AB, Chao C, Dann F. Psoriasis comorbidities. Journal of Dermatological Treatment 2008;19(1):5–21.
• Strohal R, Kirby B, Puig L; the Psoriasis Expert Panel. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2013 Dec 24. doi: 10.1111/jdv.12350. [Epub ahead of print]
• Jankowiak B, Sekmistrz S, Kowalewska B, et al. Satisfaction with life in a group of psoriasis patients. Postepy Dermatol Alergol 2013;30(2):85-90.
• Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol 1993;32(3):188–90.
• Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: A comparative study. J Dermatol ;28(8):419–23. Adamzik K, McAleer MA, Kirby B. Alcohol and psoriasis: sobering thoughts. Clin Exp Dermatol 2013;38(8):819-22.
• Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008;158(1):138-40.
• Gerdes S, Zahl VA, Weichenthal M, et al. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010;220(1):38–43.
• Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009;23(11):1311–5.
• Davidsson S, Blomqvist K, Molin L, et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol 2005;44(5):378–83.
• The burden of skin diseases 2004. 2004 [cited March 7 2007].
• URL:http://www.sidnet.org/pdfs/Burden%20of%20Skin%20 Diseases%202004.pdf31.01.2014
• Christophers E. Comorbidities in psoriasis.Clin Dermatol ;25(6):529-34. Atakan N, Doğan S. Psoriazis sistemik bir hastalık mıdır? Turk J Dermatol 2012;6(3):119-22.
• Kundakcı N, Tursen U, Babiker MO, et al. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002;41(4):220-4.
• Boffetta P, Gridley G, Lindelof B. Cancer risk in a population- based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117(6):1531–7.
• Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140(2):237–42.
• Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27(5 Pt1):716–22.
• Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194–
• Gelfand JM, Berlin J, van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139(11):1425–9.
• Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336(15):1041-5.
• Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006;142(9):1132-5.
• Wakkee M, Thio HB, Prens EP. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190(1):1-9.
• Tobin AM, Hughes R, Hand EB, et al. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case- control study. Clin Exp Dermatol 2011;36(1):19-23.
• Friedewald VE, Cather JC, Gordon KB, et al. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol 2008;101(8):1119-26.
• Friedewald VE, Cather JC, Gelfand J, et al. AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol ;102(12):1631-43.
• Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med ;124(8):775.e1-6. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735
• Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005;28(7):1769–78.
• Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156(11):1070–7.
• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4):683–9.
• Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321–8.
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829–35.
• Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141(12):1527–34.
• Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case–control study. J Invest Dermatol 2005;125(1):61–7.
• Ucak S, Ekmekci TR, Basat O, et al. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol ;20(5):517-22. Vanizor Kural B, Orem A, Cimşit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328(1-2):71–8.
• Nielsen HJ, Christensen IJ, Svendsen MN, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002;51(12):563–7.
• Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 2003;48(6):805–21; quiz 822-4.
• Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11(46):7227–36.
• Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol 1982;106(3):323–30.
• Karaca S, Fidan F, Erkan F, et al. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep Breath ;17(1):275-80. Turan H, Acer E, Aliağaoğlu C, et al. Psoriazisli hastaların klinik ve sosyodemografik özelliklerinin değerlendirilmesi. Turk J Dermatol 2013;7(2):76-80.